FY2025 EPS Estimates for Arvinas Decreased by Analyst

Arvinas, Inc. (NASDAQ:ARVN) – Equities research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Arvinas in a report released on Tuesday, November 19th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($2.98) for the year, down from their prior estimate of ($2.85). The consensus estimate for Arvinas’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Arvinas’ FY2026 earnings at ($3.64) EPS and FY2027 earnings at $1.38 EPS.

ARVN has been the topic of a number of other reports. BMO Capital Markets dropped their target price on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research note on Wednesday. Wedbush reissued an “outperform” rating and issued a $57.00 price target on shares of Arvinas in a research note on Tuesday, July 30th. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Thursday, October 31st. Finally, Barclays dropped their price target on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.08.

Arvinas Stock Performance

Shares of ARVN opened at $25.86 on Friday. The stock has a 50 day moving average price of $25.63 and a two-hundred day moving average price of $27.05. Arvinas has a 52 week low of $21.17 and a 52 week high of $53.08. The firm has a market capitalization of $1.78 billion, a P/E ratio of -5.48 and a beta of 1.96.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. During the same period in the prior year, the business earned ($1.18) EPS. The company’s revenue for the quarter was up 196.0% on a year-over-year basis.

Hedge Funds Weigh In On Arvinas

Several large investors have recently made changes to their positions in the business. M&T Bank Corp increased its holdings in shares of Arvinas by 53.5% in the 3rd quarter. M&T Bank Corp now owns 27,137 shares of the company’s stock worth $669,000 after purchasing an additional 9,462 shares in the last quarter. Barclays PLC grew its holdings in shares of Arvinas by 198.9% in the third quarter. Barclays PLC now owns 121,699 shares of the company’s stock worth $2,998,000 after acquiring an additional 80,984 shares during the period. Nomura Asset Management Co. Ltd. grew its position in Arvinas by 36.3% during the third quarter. Nomura Asset Management Co. Ltd. now owns 90,870 shares of the company’s stock valued at $2,238,000 after buying an additional 24,223 shares during the period. XTX Topco Ltd purchased a new stake in Arvinas during the third quarter valued at approximately $453,000. Finally, Zacks Investment Management lifted its position in Arvinas by 9.8% during the third quarter. Zacks Investment Management now owns 89,827 shares of the company’s stock valued at $2,212,000 after purchasing an additional 8,029 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.